MCF Advisors LLC acquired a new position in Syndax Pharmaceuticals Inc (NASDAQ:SNDX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 38,000 shares of the company’s stock, valued at approximately $169,000. MCF Advisors LLC owned 0.15% of Syndax Pharmaceuticals at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently modified their holdings of SNDX. BlackRock Inc. lifted its holdings in shares of Syndax Pharmaceuticals by 5.2% during the third quarter. BlackRock Inc. now owns 1,757,844 shares of the company’s stock valued at $14,202,000 after purchasing an additional 87,028 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Syndax Pharmaceuticals by 42.4% during the third quarter. Dimensional Fund Advisors LP now owns 795,767 shares of the company’s stock valued at $6,428,000 after purchasing an additional 237,042 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Syndax Pharmaceuticals by 560.3% during the third quarter. Renaissance Technologies LLC now owns 279,300 shares of the company’s stock valued at $2,257,000 after purchasing an additional 237,000 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Syndax Pharmaceuticals by 10.7% during the third quarter. Morgan Stanley now owns 269,595 shares of the company’s stock valued at $2,178,000 after purchasing an additional 26,043 shares during the last quarter. Finally, Macquarie Group Ltd. purchased a new position in shares of Syndax Pharmaceuticals during the second quarter valued at approximately $1,264,000. Institutional investors and hedge funds own 61.75% of the company’s stock.
Several equities analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 20th. ValuEngine lowered shares of Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Syndax Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $16.25.
NASDAQ SNDX traded up $0.25 during mid-day trading on Friday, reaching $5.44. The stock had a trading volume of 94,681 shares, compared to its average volume of 180,469. Syndax Pharmaceuticals Inc has a 1 year low of $3.39 and a 1 year high of $15.20. The firm has a market cap of $131.13 million, a P/E ratio of -1.88 and a beta of 2.14.
Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Monday, November 5th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. Syndax Pharmaceuticals had a negative net margin of 3,185.75% and a negative return on equity of 91.11%. The company had revenue of $0.38 million during the quarter, compared to analyst estimates of $0.38 million. Equities research analysts predict that Syndax Pharmaceuticals Inc will post -2.89 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “MCF Advisors LLC Acquires New Holdings in Syndax Pharmaceuticals Inc (SNDX)” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2019/01/25/mcf-advisors-llc-acquires-new-holdings-in-syndax-pharmaceuticals-inc-sndx.html.
Syndax Pharmaceuticals Profile
Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.
Recommended Story: Differences Between Momentum Investing and Long Term Investing
Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals Inc (NASDAQ:SNDX).
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.